TX-MARY-KAY
10.6.2019 08:02:10 CEST | Business Wire | Press release
Mary Kay Inc., a global beauty company and leader in skin care innovation, continues its ongoing support of the beauty and scientific communities by participating in two major global conferences in Europe this month: the 24th World Congress of Dermatology (WCD), June 10–15 in Milan, Italy and the 5th Future of Formulations in Cosmetics Summit, June 19-20, in Dusseldorf, Germany.
Held every four years, the World Congress of Dermatology is the largest dermatology meeting in the world. The WCD’s 2019 theme, “A New Era for Global Dermatology,” was the perfect match for Mary Kay to present its applied science findings and continue the scientific conversation around pollution and skin damage. On June 12, Mary Kay will host a symposium at the event titled “Environmental Stressors and Skin: Beyond UV.”
The symposium will explore the impact of external environmental aggressors on skin health, with a focus on Europe and how antioxidants can help reduce the damaging effects of pollution. Moderated by Michelle Hines, Ph.D., Director, Global Upstream Research & Technology at Mary Kay, the symposium will feature two renowned European skin experts:
- Jean Krutmann , M.D., Professor & Director at Leibniz Research Institute for Environmental Medicine – Dusseldorf, Germany.
- Stefanie Williams, M.D., Dermatologist & Medical Director at EUDELO – London, United Kingdom.
The extent of air pollution’s impact on skin and overall health was recently revealed in a new comprehensive global review by the Forum of International Respiratory Societies’ Environmental Committee, that reported air pollution may potentially affect every organ in the human body.* The report is especially relevant to the European region, as many European cities have been found to exceed air pollution limits set by the World Health Organization (WHO) or the European Environment Agency (EEA).
In fact, more than 40 towns and cities in the UK alone exceed WHO air pollution limits** and the EEA named 15 cities that are worst affected by dust particle, nitrogen dioxide and sulfur dioxide pollution*** in Germany. Excessive levels of pollution have adverse impact on overall health and are also detrimental to skin health, texture and appearance.
A pioneer of environmental medicine, Professor Krutmann has been relentlessly working in the field of skin protection. “Since I discovered in 2010 that air pollution causes skin aging and skin pigmentation, my institute has conducted a lot of research to verify this observation and to unravel the underlying mechanisms. From these studies it is now clear that long term exposure to traffic-related particulate matter (PM) is not only dangerous for our lungs and cardiovascular system, but skin health is compromised as well,” stated Jean Krutmann, M.D.
Stefanie Williams, M.D., further explained: “We might not be able to separate the damage caused to the skin by UV exposure from those caused by air pollution clinically; however, given the major research advances made in skin and air pollution science, my expectation is that the adverse effects of pollution on skin health will continue to have a growing impact in the future in high-density cities," explained Dr. Williams.
During Mary Kay’s presentation at the 5th Future of Formulations in Cosmetics Summit, Michelle Hines, Ph. D. will reveal Mary Kay’s latest research on an antioxidant complex that helps delay the onset of premature signs of skin aging related to the damaging effects of diesel exhaust particles (DEP). The breakthrough technology, found in the Mary Kay® TimeWise® Miracle Set 3D™ skin care line, provides a powerful free-radical fighting regimen with an exclusive, patent-pending, three-dimensional approach to skin aging.
“Experts have confirmed the significant negative impact of air pollution on skin and this impact will continue to grow as environmental stressors, such as DEP, and pollution levels increase, especially in densely populated urban areas,” Dr. Hines noted. “Mary Kay has discovered targeted technologies that help delay the onset of premature skin aging from unavoidable environmental and lifestyle stressors. Simultaneously, Mary Kay has been advancing scientific discussions with renowned experts around the globe to drive awareness on the negative impact of pollution on skin.”
As one of the world’s leading cosmetics and skincare industry innovators, Mary Kay’s participation in the 24th World Congress of Dermatology and the 5th Future of Formulations in Cosmetics Summit, are the latest installments in a series of global partnerships with the scientific and academic international communities.
Further demonstrating its long-lasting commitment to funding and contributing to skin health research, Mary Kay has also presented research on the topic of skin and pollution in North America at the International Investigative Dermatology meeting in May 2018, in Orlando, Florida, and in Latin America at the Reunion Anual de Dermatologos Latinoamericanos , in May 2019, in Buenos Aires, Argentina.
Every year, Mary Kay invests millions of dollars in research and development, and conducts hundreds of thousands of scientific tests on products and ingredients to ensure the highest standards of safety, quality and performance. Mary Kay holds more than 1,500 patents for products, technologies and packaging designs in its global portfolio.
*Review by the Forum of International Respiratory Societies’
Environmental Committee, Part 1: The Damaging Effects of Air Pollution
(February 2019)
** WHO Global Ambient Air Quality Database
(update 2018)
***Report by
Bundesministerium für Umwelt, Naturschutz, Bau und Reaktorsicherheit,
Berlin, Germany. 2015 (Translation: Federal Ministry for Environment,
Nature Conservation, and Nuclear Safety).
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 55 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics and nutritional supplements. Through the Mary Kay Foundation™, the company has awarded more than $78 million to cancer research and causes to help end domestic violence. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at www.marykay.com
About the WCD Meeting
The World Congress of Dermatology (WCD) - is the largest Dermatology meeting in the world. It is held every four years on various continents. The 24th WCD was held in Milano and hosted by the Italian Society of Dermatology (SIDeMaST) from June 10-15, 2019 under the auspices of the International League of Dermatological Societies. It has been over 40 years since Milan last hosted the WCD. The Meeting focused on major breakthroughs and advances in Dermatology, ranging from clinical practice to research, technology and innovation. Learn more at www.wcd2019milan.org
About the 5th Future of Formulations in Cosmetics Summit
The 5th Future of Formulations in Cosmetics Summit brings together senior executives and experts from raw materials and active ingredients manufacturers, chemical companies, major associations, technology companies, brand owners, cosmetic companies, testing companies to discuss the latest changes, challenges and developments within the industry. The 5th Future of Formulations in Cosmetics Summit will be held in Dusseldorf in Germany on June 19-20, 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190609005044/en/
Contact:
Mary Kay Inc. Corporate Communications marykay.com/newsroom 972.687.5332 or media@mkcorp.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
